ElitePepSupply

ElitePepSupplyElitePepSupplyElitePepSupply

ElitePepSupply

ElitePepSupplyElitePepSupplyElitePepSupply
  • Home
  • About
  • Our Products
  • Contact
  • More
    • Home
    • About
    • Our Products
    • Contact
  • Home
  • About
  • Our Products
  • Contact

Welcome

There's much to see here. So, take your time, look around, and learn all there is to know about us.

Our Products / Price List

Retatrutide (Reta) 30mg

Reta is a triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors. It is designed for advanced metabolic and weight management support.

Potential Benefits

$240 per vial

• Strong appetite suppression
• Increased fat loss potential
• Improved insulin sensitivity
• Better blood sugar control
• May increase metabolic rate
• Possible reduction in visceral fat
• Shown in studies to produce greater overall weight loss compared to GLP-1 alone  em

Starting Dose

1-2 mg per week

How Long a 30mg Vial Lasts:

 • 1 mg/week → 30 weeks
• 2 mg/week → 15 weeks
• 3 mg/week → 10 weeks  


(Most clients start low and gradually increase over time.) 


Trizepatide 30mg

Trizepatide is a dual-agonist peptide targeting GLP-1 and GIP receptors. It is widely used for appetite control and metabolic improvement.

Potential Benefits:

$120 per vial

• Strong appetite suppression
• Reduced food cravings
• Improved insulin response
• Better blood glucose regulation
• Consistent and sustainable weight loss
• Well tolerated for long-term metabolic support  

Starting Dose

 2.5 mg per week 

How Long a 30mg Vial Lasts:

 • 2.5 mg/week → 12 weeks
• 5 mg/week → 6 weeks
• 7.5 mg/week → 4 weeks
• 10 mg/week → 3 weeks
 

(Dose is typically increased gradually every 4 weeks.) 


Tesamorlin, CJC/IPA, TB-500, BPC-157

Available upon request

For research purposes only

Copyright © 2026 ElitePepSupply - All Rights Reserved. For research purposes only 

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept